Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
newsbox.ch
145 Leser
Artikel bewerten:
(0)

Polyphor AG: Polyphor to present new survival data for balixafortide at the 2018 European Society for Medical Oncology (ESMO) Congress

Polyphor AG / Key word(s): Conference
Polyphor to present new survival data for balixafortide at the 2018 European
Society for Medical Oncology (ESMO) Congress

18.10.2018 / 17:31

---------------------------------------------------------------------------

Allschwil, Switzerland, October 18, 2018

Polyphor to present new survival data for balixafortide at the 2018 European
Society for Medical Oncology (ESMO) Congress

Polyphor announced today that new survival data from clinical and
preclinical trials of balixafortide will be presented at the European
Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany,
October 19-23. Data at ESMO 2018 will include one poster presentation,
highlighting the full efficacy results from the Phase I trial of
balixafortide and eribulin in HER2-negative metastatic breast cancer
patients. Balixafortide is a potent and highly selective antagonist of
CXCR4, a G-protein coupled receptor (GPCR) that regulates the trafficking
and homing of both cancer cells and cells of the patient's immune system.

"We are excited by the clinical data we are presenting at ESMO this year.
The posters and presentation cover the full Phase I efficacy results of
balixafortide in combination with eribulin in patients who have undergone
multiple prior chemotherapies and have very limited treatment options," said
Dr. Debra Barker, Chief Medical and Development Officer of Polyphor. "We
look forward to further developing this clinical program in a pivotal trial
to potentially support registration for balixafortide in the U.S. and
provide a new therapeutic option to help the patients in need."

Presentation details:

Abstract #285PD: Balixafortide (a novel CXCR4 inhibitor) and eribulin in
HER2-negative metastatic breast cancer patients: A phase I trial
Speaker: Javier Cortes

- Sunday, October 21, 09:15 AM CEST, ICM-Room 1

Poster details:

Abstract #322P: Anti-tumor cell activity and in vitro profile of the next
generation CXCR4 antagonist Balixafortide
Speaker: Johann Zimmermann

- Monday, October 22, 12:45 - 13:45 PM CEST; Exhibit Hall A3 - Poster Area
Networking Hub

About Balixafortide (POL6326)
Balixafortide is a potent and highly selective antagonist of CXCR4, a
G-protein coupled receptor (GPCR) that regulates the trafficking and homing
of both cancer cells and cells of the patient's immune system. CXCR4 plays a
critical role in tumor growth, survival, angiogenesis and metastasis [i].
High CXCR4 levels have been detected in almost all human tumor types,
including breast cancer. High CXCR4 expression is known to correlate with
aggressive metastatic behavior of cancer cells and a poor prognosis [ii].

Balixafortide is being developed to improve therapy outcomes in cancer, when
used in combination with other agents. Balixafortide is the only CXCR4
antagonist in development for breast cancer and is the most advanced CXCR4
antagonist, being developed in solid tumors, being the first product
candidate to reach proof of concept. The molecule was discovered based on
Polyphor's proprietary macrocycle technology platform. Balixafortide showed
strong results in a Phase Ib/proof of concept clinical trial in combination
with eribulin in patients affected with advanced metastatic breast cancer.
The development path identified with the input of the FDA is to conduct a
single pivotal study to achieve approval in HER-2 negative metastatic breast
cancer patients who previously received at least two chemotherapeutic
regimens in the metastatic setting. Additionally, there is the possibility
of achieving an accelerated conditional approval based on interim results.
Polyphor is also conducting preclinical work to establish the potential for
balixafortide in combination with other drugs and in other oncology
indications.


About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company which has
discovered and is developing the OMPTA (Outer Membrane Protein Targeting
Antibiotics). The OMPTA are potentially the first new class of antibiotics
against Gram-negative bacteria to have reached phase III stage in the last
50 years. The company's lead product, murepavadin, (POL7080) is in Phase III
development against Pseudomonas aeruginosa - recognized as a critical
priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology
candidate, balixafortide (POL6326), which is in preparation for a pivotal
trial program in combination with eribulin in patients with advanced breast
cancer, and a pipeline of further preclinical antibiotics based on its OMPTA
platform. Polyphor is based in Allschwil near Basel and is listed on the SIX
Swiss Exchange (SIX: POLN). For more information, please visit
www.polyphor.com.

For further information please contact:

For Investors:

Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com

For Media:

Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: amu@dynamicsgroup.ch

[i] Otsuka S, Bebb G. J Thorac Oncol. 2008;3(12):1379-1383
[ii] Chatterjee S, Behnam Azad B, Nimmagadda S. Adv Cancer Res. 2014;
124:31-82

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2018 Tensid Ltd., Switzerland
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.